ERBB2 and breast cancer: In breast cancer, amid some controversy, hTIL has been detected more frequently in the triple-negative subtype or human epidermal growth factor receptor-2 (HER-2)-positive subtype than in the luminal subtype3 and is correlated with clinicopathological factors other than subtypes4,5.